<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D"><gtr:id>DBEA9B4D-7F8B-4D64-84B2-7F8F585EDD3D</gtr:id><gtr:name>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C85FEE8F-4918-4146-B2FF-E4A55389BF80"><gtr:id>C85FEE8F-4918-4146-B2FF-E4A55389BF80</gtr:id><gtr:name>Oregon Health and Science University</gtr:name><gtr:address><gtr:line1>Oregon Health and Science University</gtr:line1><gtr:line4>Portland</gtr:line4><gtr:line5>OR 97201-30</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A9A12AFB-52DD-481B-A639-8F98B1C69AA1"><gtr:id>A9A12AFB-52DD-481B-A639-8F98B1C69AA1</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>McMichael</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B45054E3-6C73-4D69-B043-6D093BBD9197"><gtr:id>B45054E3-6C73-4D69-B043-6D093BBD9197</gtr:id><gtr:firstName>Persephone</gtr:firstName><gtr:surname>Borrow</gtr:surname><gtr:orcidId>0000-0002-3877-9780</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/133048E4-2E9A-4578-A801-4CBB67C2ACE4"><gtr:id>133048E4-2E9A-4578-A801-4CBB67C2ACE4</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Brackenridge</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK012037%2F1"><gtr:id>C7D162B0-A666-48BD-8E09-83A0E559FEC8</gtr:id><gtr:title>Design of HIV vaccines that stimulate T cell and NK cell immunity</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K012037/1</gtr:grantReference><gtr:abstractText>Around 34 million people worldwide are currently infected with human immunodeficiency virus type 1 (HIV-1), the virus that causes AIDS, and 1.8 million people died of AIDS in 2010. Despite advances in the treatment and prevention of HIV infection, ~2.7 million people became newly-infected with HIV in 2010. A vaccine is therefore urgently needed to combat HIV spread. The goal of this research programme is to contribute to the development of an effective HIV vaccine. The studies below will synergise with complementary HIV vaccine research being carried out by a US-funded international consortium of which the applicants are part.
Development of effective HIV vaccines is very challenging. Most vaccines for other virus infections work by inducing the production of antibodies (Abs), proteins that bind specifically to the virus and block the establishment of infection. It is likely that a vaccine that induced Abs capable of neutralising all the circulating strains of HIV (termed broadly-neutralising (bN)Abs ) would be very effective. However HIV is a highly variable virus, which makes it difficult for vaccines to stimulate the production of Abs capable of recognising all HIV variants. Even more importantly, very few of the Abs that bind to HIV are actually able to neutralise the virus and block infection. Recent studies have shown that HIV-1 bNAbs are very difficult for Ab-producing cells (B cells) to make. Specialised helper T cells, termed follicular helper T cells (TFH), provide help to B cells for Ab production. We hypothesise that HIV-specific TFH may therefore be very important for the generation of HIV-1 bNAbs. The first aim of the proposed research will be to test this hypothesis, and to compare the ability of different vaccination strategies to induce TFH activity.
Even bNAbs are not likely to be able to block HIV infection in all cases, so it is also important for HIV vaccines to elicit other immune responses that can control virus replication after infection. HIV-specific CD8 T cells play an important role in HIV control, and vaccine-elicited CD8 T cell responses have been shown to contain HIV replication efficaciously in animal models. However the HIV-specific T cell responses elicited in human vaccine trials to date have not been adequate to control virus replication; furthermore HIV was rapidly able to mutate to escape from these responses. The second aim of the proposed research will be to develop strategies to elicit optimally-protective HIV-specific CD8 T cell responses. We will study why the first CD8 T cell responses made in natural HIV infection are often focused on just 1-2 sites in the virus (which is detrimental, as it is much easier for the virus to mutate at 1-2 sites than to escape from responses targeted to many sites), to understand how this can be overcome by vaccination. We will also study the CD8 T cell responses elicited by a new T cell-inducing vaccine developed in Oxford, which has been designed to elicit strong HIV-specific CD8 T cell responses targeted to sites in the virus where HIV is less likely to be able to mutate. We will investigate how specific aspects of the responses induced by this vaccine may enhance or reduce vaccine efficacy, and if required, will design improved T cell vaccines based on our results. 

Our third aim will be to explore the novel idea of harnessing the activity of natural killer (NK) cells (rapidly-responding cells that form part of the first line of defence against infection) in HIV vaccine design. NK cells contribute to HIV control, but until recently NK cells were not thought to share the ability of B and T cells to mount a more protective response on second exposure to a particular infection, which forms the basis of vaccination. We plan to study whether vaccines can induce long-lasting changes in NK cell responses in humans. We will also analyse how NK cell receptors recognise HIV, so that we can design NK-stimulatory vaccines to combat HIV infection.</gtr:abstractText><gtr:technicalSummary>This goal of this programme of research is to contribute to the development of an effective vaccine to combat infection with human immunodeficiency virus type 1 (HIV-1). We will focus on cellular immune responses, aiming to design strategies that: 
1) Induce CD4 follicular helper T cell (TFH) responses that enhance the generation of HIV-1 broadly-neutralising antibodies
2) Elicit optimally-protective HIV-specific CD8 T cell responses
3) Enhance natural killer (NK) cell-mediated HIV control

We will employ a combination of i. in vitro immunovirological studies; ii. advances in understanding of virus-immune system interactions during HIV infection gained by analysis of unique sample series from subjects acutely-infected with HIV and chronic patients with different clinical outcomes; and iii. insights from detailed analysis of specific aspects of the immune responses elicited in human vaccine trials, to inform the rational design of optimally-effective HIV vaccine immunogens.
 
Techniques used in the proposed work will include a breadth of cellular and molecular methods for evaluating the phenotype and functions of innate and T cell subsets, including novel assays for analysis of HIV-specific TFH activity, recently-developed methods for evaluation of na&amp;iuml;ve and pre-immunisation memory T cell repertoires and Nanostring-based gene expression analyses; together with multiple virological, proteomics-based and bioinformatics techniques with which we have expertise in-house strengthened by input from local and international collaborators.

A key element to this proposal is that it will synergise with the new NIH-funded Center for HIV/AIDS Vaccine Immunogen Design, of which the applicants are part, and with other vaccine research ongoing in Oxford. This will facilitate achievement of the objectives above both by providing access to reagents/samples and by supporting complementary studies that add value to the work in this programme.</gtr:technicalSummary><gtr:potentialImpactText>The main goal of the proposed research is to contribute to the development of an effective vaccine to combat the spread of human immunodeficiency virus type 1 (HIV-1). HIV-1 infection is associated with development of an acquired immunodeficiency syndrome (AIDS) that is almost always fatal if untreated. Around 34 million people worldwide are currently living with HIV, and HIV/AIDS caused ~1.8 million deaths in 2010. Although antiretroviral therapy can reduce virus replication and delay disease progression it does not eradicate infection and needs to be taken for life. This is expensive, and many infected individuals in developing countries where the global HIV burden is highest have little or no access to treatment. An estimated 2.7 million people became newly-infected with HIV in 2010, emphasising the urgent need for a vaccine to block HIV spread. 
Availability of an effective prophylactic HIV vaccine would be of direct benefit to individuals at risk of HIV infection, who include young adults in regions with a high HIV prevalence (e.g. parts of sub-Saharan Africa), individuals worldwide with sexual exposure to HIV-infected partners, and babies born to HIV-infected mothers. Even a partly-efficacious HIV vaccine, which could be available for use within 8-10 years, would reduce their risk of HIV infection. Some of our work could also facilitate therapeutic HIV vaccine design, which in a 10-15-year timeframe could benefit individuals already infected with HIV, enabling them to contain infection and preventing disease progression.
In addition to benefiting at-risk individuals, the availability of HIV vaccines would also benefit their families and other members of the local community. The HIV pandemic has had devastating effects on developing countries with high HIV prevalence rates, destroying families, over-burdening the health system and having a severe impact on the economy, living standards and education. Even in developed countries with lower HIV prevalence rates, HIV/AIDS treatment costs constitute a burden on the health system: annual UK HIV treatment and care costs could reach &amp;pound;750 million by 2013. A vaccine that blocked HIV spread would halt the pandemic and in the long-term would relieve its devastating effects.
By enabling the development of a HIV vaccine, our research could also benefit the commercial sector. Vaccine production for large-scale efficacy trials (in 5-8 years time) and subsequent clinical use (in 8-12 years time) by pharmaceutical companies would create jobs and boost the UK economy.

Findings from the proposed research could also help to inform the development of vaccines for other infectious diseases (e.g. malaria, tuberculosis and hepatitis virus infections) and some forms of cancer. In the medium-term (10-15 years) individuals at risk from these diseases could therefore also benefit from our work via the availability of new vaccines. Vaccines are the most cost-effective form of medical intervention for preventing death and disease, and have made a significant contribution to the increase in life expectancy over the last 50 years. The availability of new vaccines will have benefits to society as a whole. It will also reduce the burden on health services, and by increasing the health of the population, benefit the economy. There will also be direct benefits to the commercial sector via creation of small biotech companies to develop new vaccines and the need for vaccine production by the pharmaceutical industry. 

During the proposed studies students and postdoctoral staff will receive training in specific research skills, which will be of direct benefit to them and will also enhance the skill base in the UK workforce. By engaging school-children, students and the general public in our research we will also promote interest in and generate support for biomedical research, which will help the UK to remain at the forefront of science and technology, with long-term benefits for the UK economy.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1805902</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oregon Health and Science University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Vaccine and Gene Therapy Institute</gtr:department><gtr:description>Study of HLA-E restricted HIV specific T cell responses</gtr:description><gtr:id>B90C04C2-46A6-4E61-A200-97069695DF02</gtr:id><gtr:impact>1. Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, Reed JS, Gilbride RM, Ainslie E, Morrow DW, Ford JC, Selseth AN, Pathak R, Malouli D, Legasse AW, Axthelm MK, Nelson JA, Gillespie GM, Walters LC, Brackenridge S, Sharpe HR, Lopez CA, Fruh K, Korber BT, McMichael AJ, Gnanakaran S, Sacha JB, Picker LJ. Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. Science. 2016;351(6274):714-20. Epub 2016/01/23. doi: 10.1126/science.aac9475. PubMed PMID: 26797147; PubMed Central PMCID: PMC4769032.</gtr:impact><gtr:outcomeId>56d7015e0069f5.36901027-1</gtr:outcomeId><gtr:partnerContribution>Our partners first discovered that a recombinant CMV-SIV vaccine enabled monkeys to clear SIV infection and that the T cells responsible were atypical, being CD8 T cells restricted by MHC class II or MHC-E.</gtr:partnerContribution><gtr:piContribution>We brought HLA-E expertise to this collaboration. We showed that the epitopes in SIV stimulated by a recombinant CMV-SIV vaccine bound to HLA-E. Ongoing work will identify such epitopes, which may be able to clear HIV infection, in HIV.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CHAVI</gtr:description><gtr:id>B38F4BF0-C872-4922-BEE4-1744398CF640</gtr:id><gtr:impact>2008830
20463814</gtr:impact><gtr:outcomeId>U2wSAgiUuXk-1</gtr:outcomeId><gtr:partnerContribution>Access to patient samples, virus sequences, peptides, bioinformatics, statistical support.</gtr:partnerContribution><gtr:piContribution>I am one of the 7 lead PIs in the NIH Center for HIV AIDS Vaccine Immunology (CHAVI). I head the T cell and innate immunity programme. WE have initiated two studies, one on the cellular immune responses in very early HIV-1 infection (Goonetilleke et al 2009) and the other on the immune responses in people who are exposed to HIV but are uninfected. We have also initiated a genome wide association study of haemophiliacs who were exposed to HIV contaminated Factor VIII wihtoug being infected (with the CHAVI Genetics Core).</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Secondary School visit and talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6D795AC0-9642-41A1-87DA-2CC8AF2E0413</gtr:id><gtr:impact>Talk to secondary school children, mostly 6th formers.</gtr:impact><gtr:outcomeId>58b6a8747e68d3.93507562</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2FC500C2-8803-46C9-8D0D-E39B230C328E</gtr:id><gtr:title>Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2b9d77d065cedd6a178e9f762819463"><gtr:id>f2b9d77d065cedd6a178e9f762819463</gtr:id><gtr:otherNames>Abbott RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a82c523242234.09191103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95FA5E26-0A60-423F-B4FB-9226CF74A293</gtr:id><gtr:title>The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b431d2453dea62385b2509e32812be"><gtr:id>c2b431d2453dea62385b2509e32812be</gtr:id><gtr:otherNames>Wu HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5a6f2e3d514095.72158509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD5B9101-E561-431F-A249-DC2D5DF55902</gtr:id><gtr:title>HIV-1 vaccines: let's get physical.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/943afd66240b87a716970ccd9ece4a71"><gtr:id>943afd66240b87a716970ccd9ece4a71</gtr:id><gtr:otherNames>Goonetilleke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>doi_14011_013_02_017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92791474-69FA-407D-A1D2-E33C63851E5C</gtr:id><gtr:title>Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90fb521fb4609dc795b90be3158eb5e1"><gtr:id>90fb521fb4609dc795b90be3158eb5e1</gtr:id><gtr:otherNames>Song H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54525f245aa502.31892497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F20E268A-7E12-4EB5-B1E7-A99A4E5BD855</gtr:id><gtr:title>Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02b9025275703fa69f602064c14a874"><gtr:id>f02b9025275703fa69f602064c14a874</gtr:id><gtr:otherNames>Ternette N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56d6f939ae1c86.96552062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2381C3D-E213-44C5-8614-441A36694136</gtr:id><gtr:title>Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02656d87769dedab015efc3fdd127946"><gtr:id>02656d87769dedab015efc3fdd127946</gtr:id><gtr:otherNames>Demers KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>58b6a1dadc99f0.98916351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B4263C8-6D7C-481D-8BBF-B54A0C522D05</gtr:id><gtr:title>A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/228ea4b4726e7e0380e54362a3df77eb"><gtr:id>228ea4b4726e7e0380e54362a3df77eb</gtr:id><gtr:otherNames>Lane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_14011_hmg_ddt033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DA106AD-4B86-43E3-A6AF-9EE210F386A1</gtr:id><gtr:title>Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6b6ae8702947976cd643c36a0d0bf5d"><gtr:id>f6b6ae8702947976cd643c36a0d0bf5d</gtr:id><gtr:otherNames>Borrow P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>58b69e4ed199b8.45846273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AC4C3DF-7E52-4C85-A227-68BB043D3ECD</gtr:id><gtr:title>Broadly targeted CD8? T cell responses restricted by major histocompatibility complex E.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87dcaba85e32f39989d48b25c26c884f"><gtr:id>87dcaba85e32f39989d48b25c26c884f</gtr:id><gtr:otherNames>Hansen SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56d7018551a892.95655574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89110410-D1C0-4C03-90F3-6528B9C54A69</gtr:id><gtr:title>Relative resistance of HIV-1 founder viruses to control by interferon-alpha.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/158e5b51e1a75f218c5054f8cf3066c3"><gtr:id>158e5b51e1a75f218c5054f8cf3066c3</gtr:id><gtr:otherNames>Fenton-May AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>54525ca3a911a0.31098663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E60312C-FE6E-4801-8A8C-A21AED4CCE78</gtr:id><gtr:title>Ita Askonas and her influence in the field of antigen presentation.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b5bd6c0c6956fe7ccc1c69493f26744"><gtr:id>3b5bd6c0c6956fe7ccc1c69493f26744</gtr:id><gtr:otherNames>Unanue ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>54525f2486b746.20579886</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80F29944-C909-4CA5-822A-D796DAE6C2C2</gtr:id><gtr:title>Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>doi_14011_t_2013_248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2637909-8157-4E48-884F-950EB6D3AD1A</gtr:id><gtr:title>Hybrid spreading mechanisms and T cell activation shape the dynamics of HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2d31a05ff149de838f7af04b5a46315"><gtr:id>f2d31a05ff149de838f7af04b5a46315</gtr:id><gtr:otherNames>Zhang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>56d6f93a088c45.08956957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>017D3136-BE40-457C-9FE1-1637AF452C82</gtr:id><gtr:title>Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441c03103165dcfb5bb79efb38b06ef"><gtr:id>3441c03103165dcfb5bb79efb38b06ef</gtr:id><gtr:otherNames>Ondondo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56d70275758a84.27061665</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4D801CE-F315-4FEA-8550-4FB9A9EFD8B8</gtr:id><gtr:title>A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4837756eedd04b2c5e2628d1a72fe42b"><gtr:id>4837756eedd04b2c5e2628d1a72fe42b</gtr:id><gtr:otherNames>Liu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>5a6f2d2cce5825.68761239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57A5ACB4-5CE0-4FD0-8144-47EF83AFC7F5</gtr:id><gtr:title>HIV-Host Interactions: Implications for Vaccine Design.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90610a4828233b5d544306104614a0ca"><gtr:id>90610a4828233b5d544306104614a0ca</gtr:id><gtr:otherNames>Haynes BF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>56d701d26e26e0.71841302</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16E9D472-4F07-4544-BDE5-46FC86969AEA</gtr:id><gtr:title>Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c1f162a42c970dab097920114931d90"><gtr:id>8c1f162a42c970dab097920114931d90</gtr:id><gtr:otherNames>Campion SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5452556ade0e16.05340971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF261D20-514C-4580-8D6E-44636F3C46C2</gtr:id><gtr:title>Differential Immunodominance Hierarchy of CD8T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81959f2a0b1cc2014169164ebdc5f383"><gtr:id>81959f2a0b1cc2014169164ebdc5f383</gtr:id><gtr:otherNames>Adland E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5a82c522de91a4.96990013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1038B6F9-054A-4F71-8E86-0B3327AE1BDA</gtr:id><gtr:title>Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5d3fb17636d71cd9d7846c4977797bf"><gtr:id>e5d3fb17636d71cd9d7846c4977797bf</gtr:id><gtr:otherNames>Pala P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>doi_14011_I_00721_13</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83588C0E-4337-4A1C-AF49-C210B3ECB1D8</gtr:id><gtr:title>Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8T-Cell Vaccine Prevent Persistent HIV Infection?</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1943-0264</gtr:issn><gtr:outcomeId>5a6f2e57004db9.28788678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD6EEA85-822E-45C0-B6B0-E51327958C04</gtr:id><gtr:title>Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b25bd849de37f326c8014dc1ebfc7a06"><gtr:id>b25bd849de37f326c8014dc1ebfc7a06</gtr:id><gtr:otherNames>Liu MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>doi_14011_2_JCI65330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFF6F107-34C4-4722-8E16-AA7AA0B3FD68</gtr:id><gtr:title>Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffd85eaaaaa9c264e361cfa6890fe2ca"><gtr:id>ffd85eaaaaa9c264e361cfa6890fe2ca</gtr:id><gtr:otherNames>Barton JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58b6a17a6a69b1.32095532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F62CD84A-98C4-47A3-8619-3D2C0FAE9DF1</gtr:id><gtr:title>Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Science immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cf097f8eb5ecc43afdf56ad435b26df"><gtr:id>7cf097f8eb5ecc43afdf56ad435b26df</gtr:id><gtr:otherNames>Moody MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2470-9468</gtr:issn><gtr:outcomeId>58b6a02676cea5.72723323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20754628-F177-4314-8869-7812D97B41B7</gtr:id><gtr:title>Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f9a50d6c6efaefbdf91e5ad82da1a3b"><gtr:id>8f9a50d6c6efaefbdf91e5ad82da1a3b</gtr:id><gtr:otherNames>Bowles EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d6bfb57ba937.66472776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B39E6FBA-9709-4ED5-A79C-CDD317EB7D21</gtr:id><gtr:title>Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d699e537f6136ee6954dd5ce72f6d81"><gtr:id>7d699e537f6136ee6954dd5ce72f6d81</gtr:id><gtr:otherNames>Huang KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>54525f24d8b378.30871752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84AB6FAA-FF63-42C6-96B4-CBF87B486B39</gtr:id><gtr:title>Viruses transfer the antiviral second messenger cGAMP between cells.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e491ba8e5b16c64ec3cb8b381ebef5a"><gtr:id>3e491ba8e5b16c64ec3cb8b381ebef5a</gtr:id><gtr:otherNames>Bridgeman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>56d6f939d677d6.22357331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ADED067-54A4-48D1-98C1-C23DE8DC1F0A</gtr:id><gtr:title>Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bccd0fd70584179d048b43693c7805b"><gtr:id>0bccd0fd70584179d048b43693c7805b</gtr:id><gtr:otherNames>Peng Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>56d6be7a57a2b2.18524014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D663C60-A4EA-46D7-BA9F-FDEDCCEB70D4</gtr:id><gtr:title>Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13c9270163e5a00e5919e9e956c231ab"><gtr:id>13c9270163e5a00e5919e9e956c231ab</gtr:id><gtr:otherNames>Armitage AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>54525ca3545ab2.48103391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EC8DF7A-AF40-4381-9E39-3D88EF58500F</gtr:id><gtr:title>Activation of CCR2+ human proinflammatory monocytes by human herpesvirus-6B chemokine N-terminal peptide.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b58d034b7be20f9345d20c0b678b682"><gtr:id>4b58d034b7be20f9345d20c0b678b682</gtr:id><gtr:otherNames>Clark DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>54525ca4089a87.31293516</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12CE529C-27AC-4348-9ADF-EAE5D7A87B2E</gtr:id><gtr:title>Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/803ec9925955509a2337e617db569a37"><gtr:id>803ec9925955509a2337e617db569a37</gtr:id><gtr:otherNames>Tandon R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>54525ca37efe94.20133574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3870F026-6596-4B5A-8A54-C55B0342C617</gtr:id><gtr:title>Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55e9c812cfbba94f1e7e00b693cdb8e1"><gtr:id>55e9c812cfbba94f1e7e00b693cdb8e1</gtr:id><gtr:otherNames>Wang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>585d701ff2e4f0.67835233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85E190A2-7376-4B21-967A-7CE8D416AE16</gtr:id><gtr:title>Phenotypic properties of transmitted founder HIV-1.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d638ae049cd434b1cb80f314dda5afa0"><gtr:id>d638ae049cd434b1cb80f314dda5afa0</gtr:id><gtr:otherNames>Parrish NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>54525ca3d27d67.72968716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99B8897D-A56F-4109-B7FC-26559B3F67AB</gtr:id><gtr:title>HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e879436c4e9bda37faee32b2c662cd1"><gtr:id>3e879436c4e9bda37faee32b2c662cd1</gtr:id><gtr:otherNames>Wee EG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>58b6a27e6eb185.67836982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3185B706-FDE3-420D-B5F4-26A175FB2035</gtr:id><gtr:title>Unusual antigen presentation offers new insight into HIV vaccine design.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn><gtr:outcomeId>5a82c86e5146e9.79869674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>886ADE6A-0E04-4D1A-877B-2544A9F1CCD5</gtr:id><gtr:title>Vaccines that stimulate T cell immunity to HIV-1: the next step.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14eeb8916c21a02f9a4f13433a8408c8"><gtr:id>14eeb8916c21a02f9a4f13433a8408c8</gtr:id><gtr:otherNames>McMichael AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>54525f24ac3d36.36710276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C2B35A8-D094-4810-B4FB-C20CB1825A46</gtr:id><gtr:title>Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e82396dbfe08edd23f071e1a24e22764"><gtr:id>e82396dbfe08edd23f071e1a24e22764</gtr:id><gtr:otherNames>Ritchie AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>54525f2433e4b8.02908794</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K012037/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>